Atypical Pneumococcal Isolate from Blood

Abstract

Pneumonia with bacteremia accounts for the majority (70%) of cases of invasive pneumococcal diseases. Laboratory characterization of pneumococci is routinely done by sensitivity to optochin. We identified an atypical presentation of optochin-resistant pneumococci in blood isolate of a patient with sepsis. Polymerase chain reaction for autolysin (lytA) and pneumolysin (ply) was positive in the bile soluble isolate. Gene sequencing revealed synonymous single nucleotide polymorphism type of functional mutation in lytA gene. There have been emerging reports of optochin-resistant pneumococci. Diminishing relevance and reliability of optochin sensitivity testing in identifying pneumococci in clinical samples has been highlighted by this case report.

Keywords: Atypical, bacteremia, optochin resistance, pneumococci

Introduction

Isolation of Streptococcus pneumoniae from normally sterile sites such as blood, cerebrospinal fluid, synovial fluid, and pleural fluid is the hallmark of invasive pneumococcal infections. Standard biochemical test such as optochin susceptibility with a zone diameter of ≥14 mm has been the sole criteria to isolate pneumococci from clinical samples. There have been reports of emerging optochin-resistant pneumococci in a few countries.[1-3] It was first reported from Finland and sporadic reports of isolates from different geographic areas have since been documented. This report is rare because we identified atypical pneumococci in blood isolate and thereby contributing to better treatment options.

Case Report

We identified one alpha-hemolytic isolate from the blood culture of a 67-year-old male patient admitted to the intensive care unit with suspected sepsis. The Gram stain revealed characteristic lanceolate diplococci, and capsule staining by India ink was positive for pneumococci. Further tests such as optochin sensitivity, bile solubility, and inulin fermentation were done. The isolate was found to be optochin-resistant, bile soluble, and fermented inulin. Identification by both automated systems VITEK II and MALDI-TOF was S. pneumoniae, and detection of lytA gene and ply gene, encoding for virulence factors autolysin and pneumolysin, respectively, were found to be positive [Figure 1]. Further Gene sequencing was done, and the isolate was found to have the synonymous single nucleotide polymorphism type of functional mutation in lytA gene [Figures 2 and 3]. The patient responded well following treatment with ceftriaxone and was discharged after complete recovery.

Discussion

Kellogg et al.[4] in 2001 have reviewed the relevance of optochin susceptibility testing in differentiating between pneumococcal and nonpneumococcal isolates, and have

---

Figure 1: Lane 1 – DNA ladder, lane 2 – lytA (319 bp) and lane 7 – ply gene (348 bp) for optochin-resistant bile soluble blood isolate

---

How to cite this article: Veerasamy J, Jayarajan J. Atypical pneumococcal isolate from blood. Int J App Basic Med Res 2018;8:61-3.
concluded that sensitivity and specificity of optochin sensitivity testing was 99% and 98%, respectively. Data collected between 1993 and 1996 regarding pneumococci in few regions of USA by Borek et al. have been analyzed and the diminishing relevance of traditional optochin sensitivity testing in accurately identifying S. pneumoniae has been pointed out.\textsuperscript{[5]} Optochin-resistant pneumococci, bile insoluble S. pneumoniae isolates and nontypeable, unencapsulated pneumococci have been reported to comprise 2% of pneumococci isolated from normally sterile sites.\textsuperscript{[6]} Analysis of genetic and biochemical characterization of optochin sensitivity by

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{Gene sequencing for lyt A (forward primer)}
\end{figure}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3}
\caption{Gene sequencing for lyt A (reverse primer)}
\end{figure}
Veerasamy and Jayarajan: Case report: "Atypical pneumococcal isolate from blood"

Ferrándiz and de la Campa[7] (2002) highlighted that typical optochin susceptibility is decided by the nature of the F0 complex of its F0F1H+ ATPase, an enzyme that is essential for the viability of the organism. Characterization of optochin-sensitive viridians streptococci by Martín-Galiano et al. from Spain (2003) have revealed the acquisition of atp C, atpA and part of atp B from S. pneumoniae.[8] This study was reportedly conducted at Pneumococcal Reference Laboratory, Madrid, Spain. They detected an open reading frame ant in 2 optochin sensitive viridians streptococci (Streptococcus mitis and Streptococcus oralis), which was not found in S. pneumoniae, confirmed by Southern blotting technique. Comparisons of the chromosomal framework of the atp operon regions in S. pneumoniae and 2 isolates of optochin-sensitive viridians streptococci (S. mitis and S. oralis) characterized in their study and the nucleotide sequence of the atpC-atpA-atpB region, have strongly suggested the recombinant origin of optochin-sensitive viridians streptococci.

There have been reports of emerging optochin-resistant pneumococci in a few countries.[1-3] Resistant strains have point mutations in either a- or c-subunit of the H + ATPase, and demonstrate optochin MICs 4- to 30-fold higher than susceptible isolates.[9] Atypical presentation of pneumococci which was identified by pneumolysin detection in a similar case report by Kearns et al.[10] reinforces the diminishing reliability of optochin sensitivity to characterize pneumococci in clinical samples.

**Conclusion**

Diagnostic laboratories should watch out for atypical characterization of pneumococci in clinical isolates.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Muñoz R, Fenoll A, Vicioso D, Casal J. Optochin-resistant variants of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1990;13:63-6.
2. Pikis A, Campos JM, Rodriguez WJ, Keith JM. Optochin resistance in Streptococcus pneumoniae: Mechanism, significance, and clinical implications. J Infect Dis 2001;184:582-90.
3. Nunes S, Sá-Leão R, de Lencastre H. Optochin resistance among Streptococcus pneumoniae strains colonizing healthy children in Portugal. J Clin Microbiol 2008;46:321-4.
4. Kellogg JA, Bankert DA, Elder CJ, Gibbs JL, Smith MC. Identification of Streptococcus pneumoniae revisited. J Clin Microbiol 2001;39:3373-5.
5. Borek AP, Dressel DC, Hussong J, Peterson LR. Evolving clinical problems with Streptococcus pneumoniae: Increasing resistance to antimicrobial agents, and failure of traditional optochin identification in Chicago, Illinois, between 1993 and 1996. Diagn Microbiol Infect Dis 1997;29:209-14.
6. Broome CV, Facklam RR. Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the united states. Rev Infect Dis 1981;3:277-81.
7. Ferrándiz MJ, de la Campa AG. The membrane-associated F(0)F(1) ATPase is essential for the viability of Streptococcus pneumoniae. FEMS Microbiol Lett 2002;212:133-8.
8. Martín-Galiano AJ, Balsalobre L, Fenoll A, de la Campa AG. Genetic characterization of optochin-susceptible viridans group streptococci. Antimicrob Agents Chemother 2003;47:3187-94.
9. Winn W Jr., Koneman E, Procop G, Allen S, Janda W, Woods G, et al. Gram positive cocci: Part II. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. 6th ed. Ch. 13. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 689-93, 718, 1009-10.
10. Kearns AM, Wheeler J, Freeman R, Seiders PR, Perry J, Whatmore AM, et al. Pneumolysin detection identifies atypical isolates of Streptococcus pneumoniae. J Clin Microbiol 2000;38:1309-10.